Introduction: new developments in the treatment of attention-deficit/hyperactivity disorder.
Biederman
Joseph
J
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA. jbiederman@partners.org
D000279:Administration, Cutaneous; D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000503:physiopathology; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002648:Child; D016316:Guanfacine / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000627:therapeutic use; D000077408:Modafinil; D013607:Tablets
D000316:Adrenergic alpha-Agonists; D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D013607:Tablets; D008774:Methylphenidate; D016316:Guanfacine; D000077408:Modafinil